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Abstract Increased interest over the levels of pharma-
ceuticals detected in the environment has led to the need
for new approaches to manage their emissions. Inappro-
priate disposal of unused and waste medicines and release
from manufacturing plants are believed to be important
pathways for pharmaceuticals entering the environment.
In situ treatment technologies, which can be used on-site in
pharmacies, hospitals, clinics, and at manufacturing plants,
might provide a solution. In this study we explored the use
of Pyropure, a microscale combined pyrolysis and gasifi-
cation in situ treatment system for destroying pharmaceu-
tical wastes. This involved selecting 17 pharmaceuticals,
including 14 of the most thermally stable compounds
currently in use and three of high environmental concern to
determine the technology’s success in waste destruction.
Treatment simulation studies were done on three different
waste types and liquid, solid, and gaseous emissions from
the process were analyzed for parent pharmaceutical and
known active transformation products. Gaseous emissions
were also analyzed for NOx, particulates, dioxins, furans,
and metals. Results suggest that Pyropure is an effective
treatment process for pharmaceutical wastes: over 99 % of
each study pharmaceutical was destroyed by the system
without known active transformation products being
formed during the treatment process. Emissions of the
other gaseous air pollutants were within acceptable levels.
Future uptake of the system, or similar in situ treatment
approaches, by clinics, pharmacists, and manufacturers
could help to reduce the levels of pharmaceuticals in the
environment and reduce the economic and environmental
costs of current waste management practices.
Keywords Pharmaceutical waste  Thermal
decomposition  Pyrolysis–gasification  Stewardship 
Take-back strategy  Antimicrobial resistance
Abbreviations
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Introduction
Active pharmaceutical ingredients (APIs) have been
shown to persist in ground, surface, and drinking waters,
and have been detected in these water bodies around the
world; there is growing concern that these residues can
adversely impact the health of ecosystems (Musson and
Townsend 2009). It has generally been assumed that
excretion by treated individuals is the main source of
pharmaceuticals in the environment (Ort et al. 2010).
However, there is now increasing recognition that other
pathways of exposure such as emissions from manufac-
turing and the inappropriate disposal of unused medicines
could be contributing to the problem (Tong et al. 2011;
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Daughton and Ruhoy 2009; Daughton 2003; Daughton
and Ternes 1999; Larsson 2014; Seehusen and Edwards
2006; Musson et al. 2007).
Medicines can go unused for various reasons including
changes in dosage, discontinuation due to side effects, or
because the product has reached its expiry date (Boxall
et al. 2014). Across several western countries, it has been
estimated that anywhere between 3 and 65 % of prescribed
pharmaceuticals are not used by the patient (Musson and
Townsend 2009; Braund et al. 2009; Seehusen and
Edwards 2006). The majority of these unused medicines
will be disposed of down the toilet or sink to the sewerage
system, or in the household waste to landfill (Vellinga et al.
2014; Glassmeyer et al. 2009). In some regions, these two
pathways of disposal are the routes that are recommended
to the public (Musson et al. 2007). A percentage of the
pharmaceuticals released to the sewerage system can pass
through wastewater treatment plants (WWTPs) to receiv-
ing surface waters, thus adding to the environmental load.
APIs sent to landfills can leach through the site and con-
taminate groundwater (Musson and Townsend 2009; Uni-
ted States Geological Survey (USGS) 2014; Rodrı´guez-
Navas et al. 2013; Heim et al. 2004; Schwarzbauer et al.
2002; Barnes et al. 2004; Eckel et al. 1993; Holm et al.
1995). As landfill leachate is often transported to WWTPs,
APIs sent to landfill can also find their way into rivers and
streams (Lubick 2010). Disposal of unused pharmaceuti-
cals or pharmaceutically contaminated waste to landfill
could also pose a risk to wildlife which scavenge off these
sites, as demonstrated by the poisonings of avian scav-
engers by sodium pentobarbital contained in euthanized
animal carcasses (Langelier 1993; Thomas 1999; Russell
and Franson 2014; Boehringer 2004).
From an environmental perspective, the safest way to
dispose of unused medicines is to return them to the
pharmacy as part of ‘take back’ strategies, where they can
be collected and sent to be destroyed in a hazardous-waste
high-temperature incinerator (Boehringer 2004; Smith
2002). High-temperature incinerators are also used to treat
waste material from pharmaceutical manufacturing plants,
e.g., contaminated overalls, batches of APIs that do not
meet quality standards, and waste from cleaning machines.
Take-back strategies are in operation in a number of
regions, although the level of participation in these
schemes varies. Data collected in some of the most recent
studies into the use of take-back strategies found partici-
pation was highest in Sweden with 43 % of people sur-
veyed having returned unused medicines to the pharmacy
in the last 12 months (Persson et al. 2009; Tong et al.
2011). Participation was lowest in the USA with only
1.4–5.9 % (Glassmeyer et al. 2009; Kotchen et al. 2009).
A recent study in York (UK) found that 17 % of people
returned unused medicines to the pharmacy (Williamson
and Boxall 2014, unpublished data) which is similar to the
22 % obtained for a UK-wide study a decade previously
(Bound and Voulvoulis 2005). These data suggest there is
great spatial variability in take-back participation, but in
the UK at least, there has not been much change over
time.
However, take-back strategies can prove economically
costly, as the waste often has to be transported long dis-
tances to hazardous-waste incineration facilities. For waste
containing controlled substances, the transport has to be
secure, adding additional costs. In the UK, for example,
there are presently only 22 high-temperature incinerators
(DEFRA 2013), meaning that some high value wastes have
to be transported hundreds of miles across the country for
disposal. Take-back strategies also have an environmental
cost e.g., emissions of greenhouse gases during transport to
the treatment facility and emissions from the treatment
process itself. The availability of in situ treatment systems
for waste APIs would reduce disposal costs by eliminating
transportation (cost and associated CO2 emissions) and
associated security costs when wastes contain drugs with
street value. Thus in situ waste treatment for pharmaceu-
tical wastes would potentially make take-back strategies
economically viable for a greater number of pharmacists
and manufacturers. One potential in situ approach is to use
combined pyrolysis and gasification treatment technolo-
gies. These technologies have the potential to improve
environmental compliance by reducing the amount of solid
waste produced, effectively destroying the air pollutants
generated during the treatment process while simultane-
ously enabling on-site energy recovery in a way that ear-
lier, separate pyrolysis or gasification units or incinerators
cannot (Malkow 2004).
A new microscale pyrolysis–gasification waste treat-
ment technology (hereafter referred to as PGWTS, Pyrol-
ysis–gasification waste treatment system), which could be
suited for treatment of chemically contaminated wastes,
has recently been developed by Pyropure Ltd (Hampshire,
UK). Each unit is about the size of a domestic chest freezer.
At the time of this study, up to 8 kg of waste could be
treated in each run lasting 3–4 h, but the latest model will
treat 16 kg in the same time period. Materials other than
glass and metal are reduced to less than 1 % of the initial
volume by the end of the run. A waste bag or clinical waste
bin can be loaded at one end of the unit into a sealed ‘bin.’
The ‘bin’ part of the PGWTS unit is then heated up by
electrical elements (controlled automatically by software)
in the absence of air, reaching temperatures in excess of
550 C (up to 700 C). Processes of pyrolysis break the
waste down to a blackened char. The off-gases are treated
by a catalytic converter. On completion of the treatment,
the chamber is rinsed by water which then drains to the
sewerage system.
Environmental Management
123
In situ PGWTS, like Pyropure, and other new treat-
ment methods, could play an important role in controlling
the emissions of APIs to the natural environment (Online
Resource 1). However, before these systems are used in
the management of pharmaceutically contaminated
wastes, it is important that they are shown to be effective
at treating APIs. In this paper, we describe the results of
the first ever study to evaluate the use of a PGWTS for
decomposing APIs in a range of representative waste
matrices. As transformation products from treatment
processes can pose a risk to the environment (Boxall et al.
2004), we also explored the potential for known active
transformation products of the APIs to be formed during
the treatment process, using high-resolution mass spec-
trometry (Fourier transform ion cyclotron resonance mass
spectrometry). While the focus of the paper is on
assessment of the Pyropure system as an example of a
PGWTS, the assessment used could be applied to other
new treatment methods for API-containing wastes in the
future.
Materials and Methods
Selection of Test Pharmaceuticals
There are over 4000 APIs in use in Europe and it would be
a mammoth task to explore the treatability of all of these
molecules (Monteiro and Boxall 2010). As pyrolysis is a
thermal-based process, we adopted an approach where the
most thermally resistant pharmaceuticals were identified
and tested. The assumption being that, if the treatment
approach could be shown to work for these, then it should
be able to treat all organic APIs. We attempted to obtain
thermal decomposition data for the top 300 most highly
used APIs in both primary and secondary care in Great
Britain (Guo et al. 2016). Decomposition temperatures
were obtained for 249 pharmaceuticals (Fig. 1) using the
procedure presented in Online Resource 2. A selection of
14 of the most thermally stable pharmaceuticals were
selected for use in the waste treatment simulations. Three
additional APIs, diclofenac, ethinylestradiol, and carba-
mazepine, were also selected as these substances have been
previously proposed as potential priority substances under
the European Water Framework Directive (WFD) along
with ibuprofen and estradiol. Ibuprofen and estradiol had
already been included in the 14 APIs on the basis of
decomposition temperature (Lyons 2014). In the event that
these compounds are adopted as WFD priority compounds,
better controls of emissions will likely be required in the
future. The 17 substances were from a diverse range of
therapeutic classes (Table 1).
Test Chemicals and Reagents
Allopurinol (C98 %), amantadine (C98 %), aspirin
(C99 %), atenolol (C98 %), carbamazepine (C98 %),
chloramphenicol (C98 %), diclofenac (C98 %), estradiol
(C98 %), ethinylestradiol (C98 %), 5-fluorouracil (C99 %
purity), fluoxetine (C98 %), gliclazide (C98 %), ibuprofen
(98C %), indomethacin (C99 %), ketoprofen (C98 %),
sulfamethoxazole (C99 %), and verapamil (C99 %) were
purchased from Sigma-Aldrich (Gillingham, Dorset, UK).
Sodium hydroxide solution (50 % in water) and formic
acid (C95 %) used in analytical work were also purchased
from Sigma-Aldrich, UK. For the bulk waste trials (see
waste treatment simulations), ibuprofen (200 mg), and
aspirin (300 mg) tablets were purchased from a local
supermarket (Tesco, Cheshunt, UK). Chloramphenicol eye
ointment was purchased from Lloyd’s Pharmacy (4 g, 1 %
w/w, Martindale Pharmaceuticals, Romford, UK). All
solvents used were high performance liquid chromatogra-
phy (HPLC) grade, methanol ([99.9 %), acetonitrile
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Fig. 1 Cumulative percentage of pharmaceuticals looked up in
literature review against decomposition temperature (C). The
decomposition temperatures of the 17 pharmaceuticals run through
a Pyrolysis–gasification waste treatment system (PGWTS) are marked
by white circles and all pharmaceuticals (out of the 600 we looked up)
for which we found a decomposition temperature are marked with
black crosses. The white circles represent the maximum decompo-
sition temperature quoted in the literature for chloramphenicol (CHL),
sulfamethoxazole (SMX), gliclazide (GLZ), ketoprofen (KTPF),
allopurinol (ALPL), amantadine (AMN), atenolol (ATEN), estradiol
(E2), indomethacin (IND), verapamil (VPL), fluoxetine (FLX),
ibuprofen (IBF), 5-fluorouracil (5-FLU), diclofenac (DCF), carba-
mazepine (CBZ), and ethinylestradiol (EE2). The gray box represents
the typical temperature range in which the PGWTS developed by
Pyropure operate. Patient usage (based on NHS prescription cost
analysis and over the counter availability (National Health Service
(NHS) 2013) and toxicity were also considered when selecting
pharmaceuticals, meaning a pharmaceutical with higher toxicity and
or usage (E2 and CBZ) was selected over pharmaceuticals with low
usage or toxicity e.g., pioglitazone hydrochloride and glimepiride
(two black crosses between GLZ and SMX)
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([99.9 %), acetone ([99.9 %), and water were purchased
from Fisher Scientific (Loughborough, UK).
Waste Treatment Simulations
The PGWTS trial was designed in accordance with Annex
1, Sect. 1.8 of the Environment Agency Sector Guide
EPR5.07 Clinical Waste (Environment Agency (EA)
2011a). The trial was delivered in two phases: Phase 1
included all 17 pharmaceuticals and three waste types.
Phase 2, was conducted because results from Phase 1 were
inconclusive or indicated that some cross-contamination
with select APIs had occurred. Phase 2 included six of the
APIs (5-fluorouracil, ibuprofen, ketoprofen, atenolol,
estradiol, and ethinylestradiol) and one waste type. All
trials were performed at the Pyropure factory in Bordon,
Hampshire, UK.
Phase 1 Trials
The Phase 1 trials simulated the treatability of the study
pharmaceuticals in three waste types: (1) pharmacy take-
back waste (termed ‘bulk’ waste) which included blister
packs, unused tablets, and packaging; (2) manufacturing
production line waste (‘manufacturing’) which included
powdered pharmaceutical, placebo tablets, paper towels,
overalls, and lab gloves, and (3) healthcare waste which
included waste found in a yellow bins such as needles,
syringes, packaging, blister packs, and placebo tablets.
Details of the composition of each waste simulation are
provided in Online Resource 3. For the manufacturing and
healthcare waste streams a mixture of the 17 pharmaceu-
ticals, containing between 43 and 430 mg of each API, was
added to the waste in a sealed 50 mL polypropylene cen-
trifuge tube. The centrifuge tube was inserted into the
middle of the waste load where the heat presumably pen-
etrates last. For the bulk waste, three pharmaceuticals were
investigated, aspirin, ibuprofen, and chloramphenicol, and
these were added in either tablet or gel form (see Online
Resource 4).
For each simulation, the waste matrix and APIs were
placed in the PGWTS unit and treated following the
manufacturer’s guidelines. There were five runs for each of
the three waste streams: two control runs containing just
the waste mix (i.e., no pharmaceuticals) and three phar-
maceutical runs containing the waste and the pharmaceu-
ticals. The gaseous emission was passed through a water
‘trap’ to collect parent API or their transformation products
emitted in the gaseous phase. For each run, three types of
samples were collected: liquid effluent, gas trap, and
residual solids. Tap water was also taken from the site for
analysis. Samples were placed into wide-necked solvent
Table 1 The 17 pharmaceuticals selected for testing in the Pyrolysis–gasification waste treatment system (PGWTS) trials, therapeutic class,
decomposition temperature, and usage (kg/yr) in Great Britain in 2012
API Therapeutic class or use class Decomposition temperature range (C) Usage (kg/yr) Reference decomp. temp
5-Fluorouracil Anticancer, cytotoxic 282 12,648.7 1
Allopurinol Antigout 379.5–386 38,593 2
Amantadine Antiviral/AntiParkinson’s 360 626.6 3
Aspirin Analgesic 370 96,644.6 4
Atenolol Beta-blocker 303–335 26,411.5 5
Carbamazepine Antiepilepsy 190–195 45,331.9 6
Chloramphenicol Antibiotic, cytostatic 200–704 484.6 7
Diclofenac Nonsteroidal antiinflammatory drug [260 16,369.7 8
Estradiol Hormone 275–317 151.6 9
Ethinylestradiol Hormone 178 12.9 10
Fluoxetine SSRI antidepressant 200–300 6200.1 11
Gliclazide Diabetes 271–429 40,781.2 12
Ibuprofen Nonsteroidal antiinflammatory drug 180–300 151,739.9 13
Indomethacin Nonsteroidal antiinflammatory drug 230–330 837.2 14
Ketoprofen Nonsteroidal antiinflammatory drug 235–400 903.47 15
Sulfamethoxazole Antibiotic 380–600 1940.2 16
Verapamil Calcium channel blocker 300–320 6969.9 17
1: Lewis (2007), 2: Samy et al. (2010), 3: RSC (2013), 4: Ribeiro et al. (1996), 5: Pereira et al. (2007), 6: McGregor et al. (2004), 7: Macedo et al.
(1999), 8: Tudja et al. (2001), 9: Martin and Wotiz (1962), 10: Cotter et al. (1978), 11: Silva et al. (2007), 12: Zayed et al. (2010), 13: Tita et al.
(2011a), 14: Tita et al. (2010), 15: Tita et al. (2011b), 16: Fernandes et al. (1999), 17 Lide and Milne (1994)
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rinsed 125 mL amber glass bottles and stored at -20 C
prior to transportation to the laboratory (at 5 C) for
analysis for APIs.
Phase 2
In Phase 2, a mixture of the three wastes, used in Phase 1,
was investigated (See Table S1 in Online Resource 3).
Ibuprofen was again added in tablet form, the other five
APIs were added in a 50 mL centrifuge tube but in these
simulations, Vernagel (C3H3NaO2)n was also added to
create an insulating layer to surround the powdered APIs.
The addition of Vernagel is likely to mimic the effects of
excipients that would be present in a real situation. The
simulations and sampling followed the same approach as in
Phase 1 but additionally, samples from the ashpot, which
essentially contains the majority of particles removed from
the gaseous stream, were also taken and analyzed (Online
Resource 5).
Preparation of Samples for Analysis
for Pharmaceuticals
Each sample was analyzed in triplicate for APIs. The liquid
effluent and ‘gas trap’ samples (2 mL in Phase 1 and 3 mL
in Phase 2) were concentrated by a factor of ten in Phase 1
and a factor of 60 in Phase 2 using a centrifugal concen-
trator. Samples were placed inside the centrifugal con-
centrator overnight until dry, before reconstituting to
200 lL firstly by adding 100 lL of methanol and then by
adding 100 lL of HPLC grade water. Samples were vortex
mixed after the addition of both the methanol and the water
for 10 s each time. The reconstituted sample was then
passed through a syringe filter (0.2 lm PTFE (Oasis)) into
an amber glass HPLC vial containing a glass insert. In
Phase 2, the filtered sample was then concentrated again
inside glass insert (contained in the vial) using the cen-
trifugal concentrator. The sample was then reconstituted to
50 lL with 50:50 methanol:water prior to analysis.
APIs were extracted from the sludge using a method
adapted from Martin et al. (2010). Briefly, for each repli-
cate 1 ± 0.05 g of sludge (wet weight) was weighed
directly into a Pyrex glass tube. The sludge was extracted
using ultrasonication with methanol three times (2, 0.5 and
0.5 mL). Samples were ultrasonicated with the Pyrex tubes
standing in a beaker filled with deionised water, to the level
of the sample liquid, for 15 min each time. After each
extraction, samples were centrifuged for 5 min at
9609g and the supernatant was combined in a separate
glass tube. The supernatant was then dried in the cen-
trifugal concentrator, as per the effluent and gas samples,
before reconstituting to 500 lL (Phase 1) with half the
volume first added as methanol and then the remainder
added as water. The sample was vortex mixed after each
addition of solvent. In Phase 2 the total volume was
250 lL. Once reconstituted, samples were passed through a
0.2 lm (13 mm) syringe filter into an amber glass HPLC
vial (see note in Online Resource 6 about cleaning of
glassware).
For each matrix, the extraction procedure was validated
by spiking in a stock solution containing the 17 pharma-
ceuticals at known concentrations into the appropriate
matrix collected from the control runs at seven different
levels in the range 0–100,000 ng/mL. Where the calibra-
tion series was reasonably linear (R2[ 0.9) (Online
Resource 7), then the matrix-specific calibration series was
used to determine percentage recovery and quantify levels
remaining in the sample (see ‘‘Results’’ section). Where the
calibration series was not reasonably linear or recoveries
were low, the high end standards were compared with
solvent standards to determine percentage recovery. In
these cases, the calibration was done using the solvent
standards and an adjustment made for the percentage
recovery.
Analysis using Liquid Chromatography Triple
Quadrupole Mass Spectrometry (LC–MS/MS)
and LC - Fourier Transform - Ion Cyclotron
Resonance - Mass Spectrometry (LC-FT-ICR-MS)
Concentrations of pharmaceuticals in concentrated samples
or sample extracts were determined using an Applied
Biosystems/MDS Sciex API 3000 triple quadrupole mass
spectrometer interfaced with a Dionex UltiMate 3000 LCi
system, for LC–MS/MS analyses. Positive ion mode was
used in Phase 1 and both positive and negative ion modes
were used in Phase 2 analyses. For the liquid chromatog-
raphy, a Dionex Acclaim RSLC C18 Polar Advantage II
column (2.2 lm, 120 A˚, 2.1 9 100 mm) was used. Full
details of LC–MS/MS methods can be found in Online
Resource 8.
The presence of 12 known active transformation prod-
ucts of the 17 parent APIs (not all parent APIs had known
active transformation products and some had more than
one) in the samples of the emissions from the Pyropure
system was assessed. Table S8 (Online Resource 9) pre-
sents full details of molecular formulae and monoisotopic
mass for the following 12 metabolites: 5-fluoro-2-deox-
yuridine 50-monophosphate, oxypurinol, salicylic acid,
carbamzepine-10, 11 epoxide, 40hydroxy-diclofenac,
estrone, estriol, 2-methoxyestradiol, norfluoxetine, 2-hy-
droxyibuprofen, carboxyibuprofen, norverapamil. We
focussed on the transformation to products that would
retain pharmacologic activity as this was the primary
concern (relating to transformation) for the regulator in
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England (Personal communication, Robert McIntyre of the
Environment Agency, May 2014).
Our aim here was to show that the parent compound was
not being broken down into something that also possessed
pharmacological activity. We also investigated the mass
spectra of any significant chromatographic peak to assess
whether large quantities of unknown breakdown products
were being produced consistently across samples. Liquid
chromatography coupled with an ion cyclotron resonance
Fourier transform mass spectrometer (ICR-FT-MS) was
used to assess levels of these active transformation prod-
ucts. An Agilent 1200 HPLC was interfaced with a solariX
XR 9.4 T (Bruker) FT-ICR mass spectrometer (See Online
Resource 9). Where an active metabolite was identified as
being the most likely explanation for the signal, semi-
quantification was made by expressing the peak height of
the active metabolite relative to the size of the parent API
peak in a standard.
Calculation of the Percentage Decomposition
Using the total volume of the matrix (effluent, sludge, and
water used to collect the gas sample), it was possible to
determine the percentage of each API destroyed by relating
the concentration in the extracted samples and the starting
mass of the API (see Online Resource 10 Tables S9–12).
Where the analyses detected nothing, the concentration in
the sample was assumed to be half of the limit of detection
(LOD) and the percentage of the mass balance that this
constituted was calculated accordingly. A value of[99 %
decomposition of an API was considered appropriate as the
treatment success measure.
Air Emissions: Other Pollutants
A standard suite of air emissions tests was conducted by
EmCO Air Emissions Ltd (Hook, Hampshire, UK), who
are a UKAS and M-Certs accredited contractor for testing
for particulate matter (PM10), nitrogen dioxide, hydrogen
chloride, hydrogen fluoride, sulfur dioxide, volatile organic
compounds, dioxins, furans, and specific metals (mercury,
cadmium, thallium, arsenic, cobalt, chromium, copper,
manganese, nickel, lead, antimony, vanadium). Concen-
trations of these determinands in air emission samples were
expressed as a process contribution for the PGWTS using
dispersion factors. The percentage that the PGWTS con-
tributed to the environmental assessment limit (EAL) fol-
lowing the H1 guidelines of the Environment Agency
(England) for each of the determinands was used to assess
whether air emissions from treating pharmaceutical waste
would pose a risk to human health or the environment, see
Online Resource 11 Table S13 (Environment Agency (EA)
2014).
Results
The limits of detection of the analytical methods in Phase 1
and Phase 2 are presented in Tables 2 and 3. The per-
centage recovery of the extraction of pharmaceuticals from
the solid material ‘sludge’ is also presented in Table 2.
In Phase 1, the PGWTS achieved over 99 % parent API
decomposition for ten of the 17 pharmaceuticals (Fig. 2a).
The other seven pharmaceuticals had an average destruc-
tion of 94 %, with all but three pharmaceuticals having a
level of destruction in excess of 90 %, the exceptions being
atenolol, estradiol, and ethinylestradiol. There was no
apparent effect of waste type on the ability of the PGWTS
to destroy pharmaceuticals. The frequency of detection was
highly variable between matrices and pharmaceuticals (see
Online Resource 12, Tables S14 and S15 for a full break-
down of the frequency of detection). In Phase 1, five
pharmaceuticals were detected in the controls (corre-
sponding to 0.01–0.23 % of the added APIs) and 11 in tap
water (corresponding to 0.01–16.1 % of added APIs,
mean = 2.3 %) (Online Resource 12 and 13). The con-
tamination of tap water is believed to result from cross-
contamination during the sampling, as additional checks of
the factory’s tap water taken a month after the trials, and
sump and chamber drain water taken from the same
machine used in the trials did not show any trace of the
seventeen pharmaceuticals. This highlights one of the
challenges in performing studies of this type at an indus-
trial site (such as the Pyropure facility) when using highly
sensitive analytical equipment. Due to the presumed cross-
contamination, a second trial was performed on those
active ingredients where destruction levels corresponding
to \99 % destruction were determined in the Phase 1
simulation samples. In these Phase 2 trials, the destruction
levels for the worst performing APIs from Phase 1 were
above 99.9 % for five APIs and above 99.7 % for the other
API (ethinylestradiol) (Fig. 2b).
Three activemetabolites were detected in Phase 1 and five
in Phase 2 samples (out of 12 metabolites searched for).
Where they were detected, with the exception of 5-fluoro-2-
deoxyuridine 50-monophosphate (F-dUMP), the semi-
quantification suggests that the levels are likely to be such
that they are of less concern than their parent compounds
(Table 4). In Phase 1, the amount of the active metabolite of
5-fluorouracil, F-dUMP, in air was approximately 25.2 % of
the added amount of 5-fluorouracil, 60.3 % in liquid effluent
but less than 0.001 % in the sludge. The amount of F-dUMP
may well be overestimated due to differences in sensitivity
for the metabolite and parent compound. The presence of
active metabolites in control samples, of parent compounds
that were not included in these runs, suggests that cross-
contamination occurred in Phase 1 simulations. In Phase 2,
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the highest (approximate) percentage of added 5-fluorouracil
converted to F-dUMP was only 0.54 % (in liquid effluent).
F-dUMP could not be detected in air and was less than 0.1 %
of added 5-fluorouracil in the ashpot and sludge. Significant
quantities of unknown transformation products were not
consistently identified across samples in the mass spectra.
None of the non-API determinands monitored for in the
air emission studies was found to exceed short- or long-
term EALs. The highest process contribution for any
determinand was for PM10 (0.41 %). Full data on the
process contributions for each determinand can be found in
Online Resource 11.
Discussion
This study was conducted to provide the Environment
Agency with evidence of the efficacy of an alternative (to
high-temperature incineration) treatment technology for
treating pharmaceutically contaminated waste (EA 2011b).
We are not aware that others have done this before, and if
they have, this information would be commercially sensi-
tive, so it is unlikely we would gain access. Indeed, we are
not aware of any studies testing the efficacy of high-tem-
perature incineration, or any thermally or chemically (e.g.,
alkaline hydrolysis) based alternative treatment technology
for pharmaceutically contaminated wastes (World Health
Organization (WHO) 2014). This makes our data timely,
novel, and relevant to the needs of the healthcare sector,
regulators, and the waste management and pharmaceutical
industries.
The results indicate that in situ PGWTS offer an
effective treatment process for pharmaceutically contami-
nated wastes. When the findings of both trials are com-
bined, all parent APIs were demonstrated to be more than
99 % decomposed by the PGWTS (or below the LOD as
with fluoxetine). Analysis for known transformation prod-
ucts in Phase 1 suggested that the formation of known
Table 2 Limits of detection
(ng/mL) (LOD) for each of the
17 APIs in Phase 1 simulation
API Recovery of analytical extraction method (%) LOD (ng/mL)
5-Fluorouracil 28.5 100
Allopurinol 21.4 10
Amantadine 52.1 50
Aspirin 0 100
Atenolol 58.3 100
Carbamazepine 86.8 10
Chloramphenicol 75.2 50
Diclofenac 79.4 10
Estradiol 79.7 500
Ethinylestradiol 79.8 100
Fluoxetine 80.6 50
Gliclazide 45.8 100
Ibuprofen 41.6 10
Indomethacin 13.9 10
Ketoprofen 68.5 50
Sulfamethoxazole 55.5 100
Aspirin could not be recovered from the solids
Table 3 Limits of detection (LOD) and quantification (ng/mL) (LOQ) for each of the six retested APIs in Phase 2 simulation in liquid effluent,
sludge, ashpot solids, and the air emission
API Liquid effluent Sludge Ashpot Air
LOD (ng/
mL)
LOQ (ng/
mL)
LOD (ng/
mL)
LOQ (ng/
mL)
LOD (ng/
mL)
LOQ (ng/
mL)
LOD (ng/
mL)
LOQ (ng/
mL)
5-Fluorouracil 35.3 117.6 188.2 627.3 188.2 627.3 313.6 1045.5
Atenolol 2.6 8.6 1.0 3.4 0.9 2.9 1.7 5.7
Estradiol 12.6 42.1 7.8 26.1 15.7 52.2 18.3 60.9
Ethinylestradiol 63.2 210.5 35.5 117.6 70.6 235.3 84.7 282.4
Ibuprofen 180.0 600.0 120.0 400.0 150.0 500.0 300.0 1000.0
Ketoprofen 540.0 1800.0 144.0 480.0 160.0 533.3 32.0 106.7
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active metabolites and breakdown products was negligible
except for F-dUMP. F-dUMP acts slower than its parent
compound but is known to be more toxic to cells (Matuo
et al. 2009). The fact that in excess of 85 % of the added
5-fluorouracil (in Phase 1) was detected as F-dUMP, when
expressed as parent equivalents, was potentially a concern.
Thus in Phase 2, we increased the amount of 5-fluorouracil
added to the PGWTS. This revealed a maximum of only
0.5 % of the added 5-fluorouracil which was detected as
F-dUMP. It is probable that the detection of F-dUMP in
Phase 1 was an issue of contamination which was over-
estimated due to the low sensitivity for the parent
compound.
Based on the evidence of Phase 1 and 2, it is unlikely
that levels of active metabolites and transformation prod-
ucts discharged from the PGWTS would be of concern to
human health and the environment. Nevertheless, further
research is needed, particularly in the area of transforma-
tion products. The gaseous emission from the PGWTS was
sampled by bubbling through water. Therefore, only water-
soluble APIs and transformation products would be
collected. All 17 parent APIs and known active metabolites
are sufficiently water soluble for this method to enable their
collection should they have been present (e.g., see www.
drugbank.ca). While the insoluble component of the
effluent is essentially the solids that we extracted with a
polar solvent (Martin et al. 2010), we cannot rule out
nonpolar transformation products, originating from either
the APIs (Kern et al. 2010) and/or other components of the
simulated waste mix. For example, these could include
water-soluble organics such as alcohols, ethers, aldehydes,
and carboxylic acids; pyrolytic oils e.g., (asphaltenes,
aliphatics, aromatics, or polars), gases containing carboxyl
groups; and pyrolytic chars with a high ash content (Kar-
yaldirim et al. 2006). Determining whether this is the case
is now a priority for research into the efficacy of PGWTS
for treating pharmaceutically contaminated wastes.
Nevertheless, our data suggest PGWTS could provide an
in situ alternative to high-temperature incineration. By
providing households, pharmacies, hospitals, and manu-
facturers with a convenient and safe alternative to dispos-
ing of unused medicines to sewer or in solid waste PGWTS
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the fate of pharmaceuticals
tested in a Pyrolysis–
gasification waste treatment
system (PGWTS) in Phase 1
(a) and Phase 2 (b). The
percentage that was destroyed is
given by white-dotted bars, the
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could reduce the amounts of APIs being inappropriately
disposed of. Ultimately, PGWTS could contribute to
reducing pharmaceutical contamination of both the terres-
trial and aquatic environments (e.g., McClellan and Halden
2010; Kasprzyk-Hordern et al. 2010).
Inappropriate disposal of unused pharmaceuticals has
been identified as an issue in several developed countries
(Daughton and Ruhoy 2009, 2013; Thach et al. 2013; Tong
et al. 2011). Data are highly variable among countries, and
in some cases among studies conducted within the same
country. A number of factors could affect the data reported
by these studies: e.g., data collection method, question
types, demographics, sample size, and changes in attitudes
over time. Studies in Sweden and Germany (Persson et al.
2009; Tong et al. 2011) found only 3 and 7 %, respectively
of unused medicines were disposed of in household waste,
while Lithuania and Kuwait had 87–89 % and 97 %,
respectively (Krupiene and Dvarioniene 2007; Abahussain
and Ball 2007; Abahussain et al. 2006). However, in the
US (45–54 %; Kotchen et al. 2009; Glassmeyer et al.
2009), the UK (63 %, Bound and Voulvoulis 2005), and
Republic of Ireland (51 %, Vellinga et al. 2014) disposal in
household waste appears similar. For disposal down the
sink or toilet,\1 % did this in Sweden and New Zealand
(Persson et al. 2009; Braund et al. 2009) while in the US
54 % dispose of medicines to the toilet and 35 % down the
sink (Seehusen and Edwards 2006; Glassmeyer et al.
2009). Other fates for unused medicines included storing at
home in case of future personal use or needs of a friend/
relative, burning, placing in recycling boxes, or disposing
to hazardous waste.
Providing the public with knowledge of appropriate
disposal methods for unused medicines and ensuring con-
venient access to take-back strategies should help to
decrease inappropriate disposal (Persson et al. 2009; Thach
et al. 2013). In Sweden, as many as 85 % of respondents
Table 4 Active metabolites detected in Phase 1 and Phase 2, in
samples of air, mains water (i.e., water straight from the tap taken at
the same time as the unit was being drained and washed out with tap
water), liquid effluent, the solid ashpot residue and the sludge (solid
part of the effluent)
Phase 1 Phase 2
API run 1 API run 2 API run 3
Metabolite Approximate
parent
equivalent %
Metabolite Approximate
parent
equivalent %
Metabolite Approximate
parent
equivalent %
Metabolite Approximate
parent
equivalent %
Air F-dUMP 25.2 – – – – 2-me 0.03
Mains
water
NA NA 2-hydoxyIBF
2-me
0.028
0.050
2-me 0.010 2-me 0.007
Liquid
Effluent
F-dUMP
2-me
SA
60.3
0.04
0.35
– – F-dUMP 0.54 2-hydroxyIBF 0.014
Solid
Ashpot
NA NA 2-me
F-dUMP
Est
0.00002
0.02
0.00003
2-me
F-dUMP
Est
0.00007
0.012
0.0003
carboxyIBF
Est
0.0005
0.0005
Sludge
rep 1
2-me 0.0007 2-me
2-hydroxyIBF
F-dUMP
carboxyIBF
Est
0.007
0.012
0.024
0.006
0.0016
2-me
2-hydroxyIBF
carboxyIBF
Est
0.007
0.00011
0.0040
0.00014
2-me
F-dUMP
Est
0.00009
0.042
0.00014
Sludge
rep 2
NA NA Est 0.0015 2-me
2-hydroxyIBF
carboxyIBF
Est
0.00009
0.011
0.0056
0.000023
2-me
F-dUMP
carboxyIBF
Est
0.0001
0.043
0.001
0.0007
In Phase 1, means are presented for the three waste types (bulk, manufacturing, and sharps as only 15 samples were run in total (3 air, 3 sludge,
and 9 liquid effluent). In Phase 2, a larger number of samples were analyzed and so the data are presented separately for each run. The
metabolites detected were: 5-fluoro-2-deoxyuridine 50-monophosphate (F-dUMP)), 2-methoxyestradiol (2-me), estrone (Est), 2-hyroxyibuprofen
(2-hydroxyIBF), and carboxyibuprofen (carbIBF). Where an active metabolite was detected, the concentration was estimated in terms of parent
equivalent and then related to the percentage of the starting mass that this was equivalent to. For control and blank runs containing only
Polyethylene terephthalate (PET) and all mains water samples, no API was added and so detection must be due to background levels in the tap
water. Note the F-dUMP parent equivalent is likely to be overestimated due to the low sensitivity of the MS assay for its parent compound
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knew that returning unused medicines to the pharmacy was
the appropriate way to handle them, and 43 % said they
had done so in the last 12 months (Persson et al. 2009).
However, in the UK, a 2013–14 survey suggested only
17 % of people use take-back strategies (Williamson and
Boxall 2014, unpublished data) and as many as 30 % of
people were found to dispose of medicines inappropriately.
Furthermore, a study in the Republic of Ireland found only
6 % used take back and 72 % disposed of medicines
inappropriately (Vellinga et al. 2014). However, this is still
better than reported participation in the USA (1.4 %)
(Glassmeyer et al. 2009). Based on these studies, it appears
a lack of knowledge around appropriate disposal and
access to take-back strategies are the main reasons for
inappropriate disposal (Thach et al. 2013). Furthermore,
initiatives that have not advised best practice for handling
unused medicines such as the SMARxT disposal partner-
ship in the USA are also likely to have contributed to
pharmaceutical emissions from landfill. This initiative
recommends that unused medicines are crushed, mixed
with unappealing material such as cat litter (to prevent
scavenging and illicit use) and disposed of to landfill in a
sealable bag or box. Such strategies are unlikely to protect
the environment, as a sealed bag or box can easily be
crushed and opened in the landfill (Musson and Townsend
2009). The pharmaceuticals can then end up in leachate.
Both leachate and flushed (or rinsed) medicines can end up
in the WWTP where removal is often incomplete, thus
leading to contamination of the aquatic environment
(Daughton 2003).
The study of pharmaceutical contamination of leachate
has been largely neglected (Musson and Townsend 2009).
Recent studies in the US and Spain have detected several
pharmaceuticals at the lg/L level in landfill leachate (in-
cluding amoxicillin, carbamazepine, furosemide, ibupro-
fen, and omeprazole) (United States Geological Survey
(USGS) 2014; Rodrı´guez-Navas et al. 2013). Lubick
(2010) reported details of a similar study from Maine in
which paracetamol was detected in leachate at 117 lg/L,
ciprofloxacin at 269 ng/L, and even cocaine was detected
at 57 ng/L. Many landfills pipe their leachate to wastewater
treatment plants (Musson and Townsend 2009). Some
healthcare facilities advise staff to flush unused medicines
down the toilet or rinse down the sink and in these
instances APIs will be released directly to the sewerage
system (Daughton 2003; Boxall et al. 2014; Mackridge
2005).
In healthcare facilities where medicines are rinsed down
the sink, antibiotics are often used (Bumpass et al. 2014).
Antibiotic resistance (Starlander and Melhus 2012), and
particularly resistance to ‘last resort’ carbapenem antibi-
otics (Kotsanas et al. 2013), is of particular concern.
Repeated washing of traces of these medicines down can
lead to the development of a biofilm containing persistent
gram-negative bacteria from multiple genera (Kotsanas
et al. 2013). This biofilm acts as a reservoir for the trans-
mission of antimicrobial resistance making nosocomial
transmission highly likely (Kotsanas et al. 2013). Cleaning
and replacing sinks with better designed ones have both
been suggested by some as the way towards antimicrobial
stewardship (Kotsanas et al. 2013). However, this is a
rather narrow-minded view of stewardship which simply
transfers the problem out of the hospital and into the
environment. PGWTS and other in situ waste treatment
technologies offer a real solution. By destroying unused
antibiotics and antibiotic contaminated waste at source, the
risks of these drugs, and the transfer of antimicrobial-re-
sistant bacteria to the environment in this way could be
eliminated. This could also be important at manufacturing
plants. Although manufacturing emissions of pharmaceu-
ticals to the environment are concentrated in specific areas,
they may also be significant, particularly for antibiotics, as
their emission even at trace levels will promote the
development of antimicrobial-resistant microorganisms
(Larsson 2014). To this extent, PGWTS could still have a
significant role to play in terms of human and environ-
mental health at the global scale (Larsson 2014).
In situ PGWTS could realistically be installed at phar-
macies, manufacturers’ sites, hospitals, and healthcare
facilities across the world. The adoption of alternative
treatment technologies such as PGWTS could make take-
back strategies much more effective than they currently
are. Pharmacies and clinics are likely to be willing par-
ticipants in such strategies as in situ waste management
comes with economic incentives in addition to environ-
mental benefits. By removing the need to transport waste
across potentially long distances to high-temperature
incinerators (there are currently only 22 in the whole of the
UK (DEFRA 2013)), fuel, labor, and security (in the case
of wastes containing controlled substances such as mor-
phine) as well as reducing CO2 emissions. The cost-bene-
fits to the user of using PGWTS over separate collections
and high-temperature incineration are compelling, which is
an important factor in the likelihood of their incorporation
in take-back strategies. For a typical pharmaceutically
contaminated medical waste, which has a high plastic
content and assume its calorific value is 27 MJ/kg, the
electrical cost to process this in a PGWTS is approximately
$300 per metric tonne. Factoring in costs associated with
regulatory requirements, water, and maintenance costs
adds an additional $180 per metric ton, giving a total
running cost of $480 per metric ton for PGWTS.
A waste producer can pay between $3748 and $4410 per
metric ton (or $1.70 to $2.00 per lb) for collection, trans-
port, and treatment of hazardous waste (Rich et al. 2013).
Taking the midrange figure of $4000 per metric ton, the on-
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site PGWTS could save the user around $3520 per ton of
waste. In addition to these costs savings, the PyroPure
PGWTS generates 2.68 kW h per ton of usable energy in
the form of heat for a high plastic content load. This means
a user processing 20 tons per year would generate
53,600 kW h of free heat (worth the equivalent of $5400 in
replacing electricity at $0.1/kW h). Combining the value of
energy generated with reduced costs in waste collection
and processing, PGWTS offer approximately 95 % cost
savings compared to collection high-temperature inciner-
ation. To purchase a single PGWTS currently costs
approximately $75,000. For a user treating around 20
metric tons per year, the PGWTS investment would start to
make cost savings in a little over a year. These fig-
ures suggest PGWTS are economically viable and envi-
ronmentally friendly which could help improve the density
with which take-back strategies are offered to a population.
As it is estimated that up to 65 % of prescribed
medicines remain unused by patients (Boxall et al. 2014),
but only around 17 % are being safely disposed of in the
UK (Williamson and Boxall 2014, unpublished data)
(ranging from 1.4–65 % in other Western countries) (Tong
et al. 2011; Persson et al. 2009; Glassmeyer et al. 2009;
Vellinga et al. 2014; Musson and Townsend 2009;
Daughton 2003; Seehusen and Edwards 2006; Musson
et al. 2007; Isacson and Olofsson 1999; Cameron 1996),
there is clearly a significant proportion of these unused
medicines which are disposed of in ways that result in
environmental contamination. Any technology that will
help to close the gap between what is unused and what is
disposed of in take-back strategies can only be beneficial to
the environment.
To ensure the success of PGWTS, we believe they
should be implemented as part of wider stewardship
strategies which involves a wide range of stakeholders.
Doctors should prescribe smaller doses to help reduce the
number of unused medicines in households (Daughton and
Ruhoy 2013). Governments and manufacturers should set
up education and advertising strategies to raise the public’s
awareness of the availability of take-back facilities in their
area while highlighting the consequences of flushing to
sewer or disposing of medicines in household waste (EU
2015).
Changing people’s attitudes and raising awareness of
take-back strategies will be paramount to a successful
outcome. Strategies such as the EU’s ‘no pills in waters’
cooperation project have been in place for a while in
Europe to encourage greater use of take-back strategies
(EU 2015). In such strategies, partnerships between envi-
ronmental, social scientists, and communications and
software experts have been demonstrated to be very
important to gain an idea of the scale of the problem and
create a pathway towards making changes for the better.
For example, connecting with young people to inform them
about the issue of pharmaceuticals in the environment was
identified as an important issue to ensure the future sus-
tainability of such strategies (EU 2015). Other means of
connecting with demographic groups (e.g., the elderly and
their carers) could be through strategies that introduce
information boards in doctors’ surgeries, pharmacies,
placing adverts on healthcare-related websites and adding
labels to pharmaceutical packaging.
Conclusions
PGWTS have the potential to make significant reductions
to current levels of pharmaceutical contamination in the
environment. Not only are there potential benefits in terms
of pharmaceutical contamination of the environment, there
are also financial and environmental incentives. This makes
PGWTS a viable alternative to waste collection and
transport to high-temperature incinerators. The initial
investment in a PGWTS could be repaid in a little over a
year due to approximately 95 % cost-saving compared
with high-temperature incineration (Rich et al. 2013).
Alternative treatment (to high-temperature incineration)
technologies for pharmaceutically contaminated waste will
only be effective if the public and healthcare workers gain
a greater awareness of the consequences of inappropriate
disposal of API-containing wastes and with it a sense of
environmental responsibility. Education can pave the way
towards a cultural change in the way that we deal with
unused medicines and in situ waste treatments will repre-
sent a convenient disposal option that can help smooth this
transition.
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